BACKGROUND & AIMS: Nonalcoholic fatty liver disease (NAFLD) is characterized by excessive triglyceride accumulation in hepatocytes. Expression of the lipid droplet protein adipose differentiation-related protein (ADRP) is increased in NAFLD, but whether this is causally linked to hepatic lipid metabolism is unclear. We postulated that a reduction in ADRP would ameliorate hepatic steatosis and improve insulin action. METHODS: Leptin deficient Lep(ob/ob) and diet-induced obese (DIO) mice were treated with antisense oligonucleotide (ASO) against ADRP, and effects on hepatic and serum lipids and glucose homeostasis were examined. RESULTS: ADRP ASO specifically decreased ADRP mRNA and protein levels in the livers of Lep(ob/ob) and DIO mice, without altering the levels of other lipid droplet proteins, that is, S3-12 and TIP47. ADRP ASO suppressed expression of lipogenic genes, reduced liver triglyceride content without affecting cholesterol, attenuated triglyceride secretion, and decreased serum triglyceride and alanine aminotransaminase levels. The reduction in hepatic steatosis by ADRP ASO was associated with improvement in glucose homeostasis in both Lep(ob/ob) and DIO mice. CONCLUSIONS: This study demonstrates a crucial role for the lipid droplet protein ADRP in regulation of lipid metabolism. Reduction in hepatic ADRP level using an antisense oligonucleotide reverses hepatic steatosis, hypertriglyceridemia, and insulin resistance in obese mice, suggesting that ADRP may be targeted for the treatment of NAFLD and associated lipid and glucose abnormalities.
BACKGROUND & AIMS:Nonalcoholic fatty liver disease (NAFLD) is characterized by excessive triglyceride accumulation in hepatocytes. Expression of the lipid droplet protein adipose differentiation-related protein (ADRP) is increased in NAFLD, but whether this is causally linked to hepatic lipid metabolism is unclear. We postulated that a reduction in ADRP would ameliorate hepatic steatosis and improve insulin action. METHODS:Leptin deficient Lep(ob/ob) and diet-induced obese (DIO) mice were treated with antisense oligonucleotide (ASO) against ADRP, and effects on hepatic and serum lipids and glucose homeostasis were examined. RESULTS:ADRPASO specifically decreased ADRP mRNA and protein levels in the livers of Lep(ob/ob) and DIO mice, without altering the levels of other lipid droplet proteins, that is, S3-12 and TIP47. ADRPASO suppressed expression of lipogenic genes, reduced liver triglyceride content without affecting cholesterol, attenuated triglyceride secretion, and decreased serum triglyceride and alanine aminotransaminase levels. The reduction in hepatic steatosis by ADRPASO was associated with improvement in glucose homeostasis in both Lep(ob/ob) and DIO mice. CONCLUSIONS: This study demonstrates a crucial role for the lipid droplet protein ADRP in regulation of lipid metabolism. Reduction in hepatic ADRP level using an antisense oligonucleotide reverses hepatic steatosis, hypertriglyceridemia, and insulin resistance in obesemice, suggesting that ADRP may be targeted for the treatment of NAFLD and associated lipid and glucose abnormalities.
Authors: Andrew S Greenberg; Rosalind A Coleman; Fredric B Kraemer; James L McManaman; Martin S Obin; Vishwajeet Puri; Qing-Wu Yan; Hideaki Miyoshi; Douglas G Mashek Journal: J Clin Invest Date: 2011-06-01 Impact factor: 14.808
Authors: David J Orlicky; Andrew E Libby; Elise S Bales; Rachel H McMahan; Jenifer Monks; Francisco G La Rosa; James L McManaman Journal: J Physiol Date: 2019-01-02 Impact factor: 5.182
Authors: Gladys M Varela; Daniel A Antwi; Ravindra Dhir; Xiaoyan Yin; Neel S Singhal; Mark J Graham; Roseanne M Crooke; Rexford S Ahima Journal: Am J Physiol Gastrointest Liver Physiol Date: 2008-07-31 Impact factor: 4.052
Authors: Yumi Imai; Hiral R Patel; Nicolai M Doliba; Franz M Matschinsky; John W Tobias; Rexford S Ahima Journal: Physiol Genomics Date: 2008-10-14 Impact factor: 3.107